Epidemiology: The incident population of acute lymphoblastic leukemia is predicted to increase between 2015 and 2035.
By Keane Tzong, Epidemiologist
31 March 2016
I am an Epidemiologist at Datamonitor Healthcare. I received my MPH in Epidemiology from Columbia University’s Mailman...
Read full bio
Acute lymphoblastic leukemia (ALL) accounts for 0.3% of all diagnosed cancers. ALL is rare in adults, but it is the most common childhood leukemia as well as the most common childhood cancer. Datamonitor Healthcare predicts that there will be limited positive growth in the incident ALL population in the US, France, Germany, and the UK between 2015 and 2035. There will be negative growth in the incident ALL population in Japan, Italy, and Spain. The US is expected to see the greatest increase in the number of incident cases of ALL. Population aging, in addition to increasing incident rates – particularly among elderly individuals – will alter the composition of the incident population. Meanwhile, the development of improved treatments and subsequent improvements in survival are likely to contribute to an increase in the size of the prevalent patient population in the future.
Treatment: The introduction of tyrosine kinase inhibitors to the ALL market has altered the treatment paradigm
Philadelphia chromosome-positive (Ph+) patients represent the largest patient segment in the acute lymphoblastic leukemia (ALL) market. These patients have a poor prognosis, but the introduction of tyrosine kinase inhibitors (TKIs) has improved treatment outcomes and brought the use of hematopoietic stem cell transplantation (HSCT) in some younger adult patients into question. Treatment with chemotherapy and a TKI may be quite effective in these patients and could be a more suitable treatment option given the risks associated with HSCT. Datamonitor Healthcare has analyzed the prescribing trends of 226 hematologists across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), focusing on the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The results of this survey indicate that the TKIs Gleevec (imatinib; Novartis) and Sprycel (dasatinib; Bristol-Myers Squibb/Otsuka) are popular in all phases of treatment of ALL. Novel therapies in the pipeline, such as CAR-T immunotherapies and CD22 surface antigen-targeting drugs, are expected to have great clinical promise.
Approved TKIs indicated for the treatment of adults with acute lymphoblastic leukemia
|Gleevec (imatinib)||Novartis||Adults with relapsed or refractory Ph+ ALL
Pediatric patients with newly diagnosed Ph+ ALL in combination with chemotherapy
|Sprycel (dasatinib)||Bristol-Myers Squibb/Otsuka||Adults with Ph+ ALL resistant or intolerant to prior therapy|
|Iclusig (ponatinib)||Ariad||Adults with Ph+ ALL resistant or intolerant to prior TKI therapy|
|Note: indications based on US prescribing information.|
|ALL = acute lymphoblastic leukemia; Ph+ = Philadelphia chromosome-positive; TKI = tyrosine kinase inhibitor|
|Source: Bristol-Myers Squibb, 2013; Ariad, 2013; Novartis, 2013|
Datamonitor Healthcare’s Acute Lymphoblastic Leukemia: Epidemiology uses historical incident rates and survival data to forecast incident and prevalent populations of acute lymphoblastic leukemia in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) between 2015 and 2035.
Datamonitor Healthcare’s Acute Lymphoblastic Leukemia: Treatment explores the impact of tyrosine kinase inhibitors in the ALL market, as well as a detailed look at current treatment algorithms and prescribing influences.
Get your free demo today – simply fill out the form to the right.